Sakar Healthcare Ltd

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 July 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Sakar Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is underscored by a mix of technical indicator signals, including MACD, RSI, moving averages, and Bollinger Bands, which collectively suggest an improving price momentum and potential for further upside in the near term.

Sakar Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent day decline of 3.07%, the stock’s year-to-date return of 96.04% significantly outpaces the Sensex’s negative 9.04% return, signalling underlying strength amid mixed technical indicators.

Sakar Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a marked improvement in its financial performance for the quarter ended June 2026. The company’s recent results reveal robust revenue growth, significant margin expansion, and improved return ratios, signalling a very positive shift in its financial trend despite a recent downgrade in its Mojo Grade from Buy to Hold.

Sakar Healthcare Ltd., a Gujarat-based pharmaceutical manufacturer, delivered robust top-line growth in Q1 FY27 with net sales rising 38.36% year-on-year to ₹72.97 crores, though net profit growth of 120.13% to ₹10.28 crores came with a sequential dip of 6.72%. The stock, trading at ₹802.20 with a market capitalisation of ₹1,903 crores, has declined 3.07% following the results announcement, reflecting investor concerns about margin compression despite the strong revenue momentum.

Sakar Healthcare Ltd is rated Buy by MarketsMOJO, with this rating last updated on 15 May 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 20 July 2026, providing investors with the most up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 15 May 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 09 July 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 15 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 June 2026, providing investors with the latest insights into its performance and outlook.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 15 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 17 June 2026, providing investors with the most up-to-date insight into the stock’s performance and outlook.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 15 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Sakar Healthcare Ltd is rated Buy by MarketsMOJO, with this rating last updated on 15 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 June 2026, providing investors with the most up-to-date view of the company’s fundamentals and market performance.

At Rs 837.75, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Sakar Healthcare Ltd locked at its upper circuit of 10% on 25 May 2026, with buyers queuing and no sellers willing to part with shares.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 15 May 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the stock’s current position as of 25 May 2026, providing investors with the latest insights into its performance and outlook.

A 143.23% stock return in one year. A 91.32% growth in net profit over the same period. The gap between those two numbers — roughly 52 percentage points — is driven by the market’s willingness to pay more for each rupee of Sakar Healthcare Ltd’s earnings. That willingness is the story behind this micro-cap’s multibagger status.

Sakar Healthcare Ltd is rated Buy by MarketsMOJO, with this rating last updated on 14 May 2026. While the rating change occurred on this date, the analysis and financial metrics discussed here reflect the stock's current position as of 14 May 2026, providing investors with an up-to-date view of the company’s standing.